Gilead Sciences (GILD) to Release Quarterly Earnings on Thursday

Key Points

• Q1 2026 earnings due Apr 23 after the close: Analysts expect $2.10 EPS and $7.39 billion in revenue, and Gilead has set FY 2026 guidance of roughly $8.45–$8.85 EPS.
• Gilead recently beat prior-quarter estimates (EPS $1.86 vs. $1.83; revenue $7.93B) and raised its quarterly dividend to $0.82 ($3.28 annual, ~2.3% yield), supporting income-focused investor appeal.
• Positive commercial catalysts include expanded public-health commitments for the HIV prevention drug lenacapavir (adding capacity for up to ~1M more people, ~3M total through 2028), and Wall Street sentiment is broadly constructive with a consensus "Moderate Buy" and an average target around $156.77.

Gilead Sciences (NASDAQ:GILD - Get Free Report) will likely be issuing its Q1 2026 results after the market closes on Thursday, April 23rd. Analysts expect the company to announce earnings of $2.10 per share and revenue of $7.3902 billion for the quarter. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, April 23, 2026 at 4:30 PM ET.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business's revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.90 earnings per share. On average, analysts expect Gilead Sciences to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $139.77 on Thursday. The business has a 50 day moving average of $144.86 and a 200 day moving average of $131.05. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a market cap of $173.49 billion, a PE ratio of 20.65, a P/E/G ratio of 1.87 and a beta of 0.39. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's payout ratio is presently 48.45%.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. UBS Group raised their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Scotiabank increased their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, February 11th. Cantor Fitzgerald lowered their price objective on shares of Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, April 10th. Finally, Jefferies Financial Group started coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a "buy" rating and a $180.00 price objective on the stock. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $156.77.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Large public-health deals boost revenue visibility and long-term demand: PEPFAR, The Global Fund and the U.S. State Department expanded commitments for Gilead’s twice-yearly injectable HIV prevention drug lenacapavir, adding capacity to reach up to an additional 1 million people (raising total commitments to ~3 million through 2028). This supports recurring demand and institutional revenue streams for Gilead. PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir US-Led Partnership To Provide 1 Mln Lenacapavir
• Positive Sentiment: Analyst optimism: A Citigroup analyst publicly expects GILD shares to rise, which can support near-term buying interest and re-rate sentiment among investors. Gilead Sciences NASDAQ: GILD Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Stock movement context: Recent coverage noted that Gilead gained intraday but lagged broader market gains, reflecting mixed sentiment despite company-specific positives. This explains some muted upside versus peers. Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
• Neutral Sentiment: Macro/earnings-signal coverage: Screening tools and notes on earnings momentum include Gilead among medical names to watch ahead of results, which can drive short-term trading flows but not immediate fundamental change. Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
• Negative Sentiment: Small analyst downward revision: Zacks lowered its Q3 FY2026 EPS estimate modestly (from $2.30 to $2.25), signaling slight near-term earnings pressure or conservatism in modeling; investors may view this as a heads-up on quarter-to-quarter variability.
• Negative Sentiment: Reputational and pricing pressure: Activist group AHF publicly protested Gilead over alleged high AIDS drug pricing, a reputational risk that can attract regulatory/political scrutiny and pressure pricing in sensitive markets. Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing
• Negative Sentiment: Competitive pressure in oncology: Peer Bristol Myers’ CAR-T (Breyanzi) is scaling rapidly, which tightens competition in cell therapy markets where Gilead also competes (affecting long-term franchise dynamics). Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares in the company, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company's stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 293,280 shares of company stock worth $42,074,690 over the last three months. 0.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of GILD. Sivia Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock valued at $464,000 after acquiring an additional 602 shares during the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $215,000. Brighton Jones LLC raised its holdings in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Binnacle Investments Inc lifted its position in Gilead Sciences by 11.8% during the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company's stock valued at $87,000 after purchasing an additional 83 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Gilead Sciences by 135.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 713 shares of the biopharmaceutical company's stock worth $79,000 after purchasing an additional 410 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.